Developer docs
API playgroundTry for free, no card

Search company profiles

TeleDaaS

Full company profile

uuid02m142o

Namestring
TeleDaaS
Legal namestring
TeleDaaS PLLC
Websiteurl
teledaas.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

TeleDaaS is a U.S.-based medical practice (TeleDaaS PLLC, Illinois) that delivers cloud-based, physician-approved personalized dosimetry plans for Y90 radioembolization cancer treatments, primarily targeting hospitals, health systems, and physician practices treating liver cancer. The service is positioned around the clinical finding that personalized dosimetry substantially improves patient outcomes—referenced DOSISPHERE-1 trial data shows 2.3x improvement in median survival and an 8-fold increase in eligibility for curative surgery versus standard dosimetry—while also capturing full reimbursement under existing CPT codes by ensuring complete, billable documentation (the company states 99% of sites may be underbilling without proper dosimetry documentation). The product reduces physician time by 1-2 hours per case, is delivered entirely via cloud with no on-premise IT installation, and integrates with existing hospital imaging workflows.

The core technology is a dosimetry-as-a-service platform licensed from Mirada Medical Ltd., whose software carries ISO 13485 and ISO 27001 certifications and has been used across multiple clinical trials. TeleDaaS operates two service lines: "For The Clinical Practice" (treatment planning for hospitals treating Y90 patients) and "DoseLab" (research/clinical-trial dosimetry for CROs and pharmaceutical manufacturers developing radiopharmaceuticals). The team is small (1-10 employees) and is led by Co-Founder/CEO Dr. Shamar Young (Chief of Interventional Radiology at the University of Arizona), Co-Founder/COO Shelby Schweitzer, and CMO Dr. Mark Crockett, supported by PhD-level scientific advisors with over 90 years of combined experience in medical imaging, physics, and clinical translation.

TeleDaaS makes money by selling dosimetry treatment planning as a professional service to enterprise healthcare buyers on a consultative, quote-based model with a pilot program for early adopters. Its go-to-market is sales-led and direct, targeting U.S. hospitals, health systems, CROs, and pharmaceutical manufacturers, with thought-leadership content, an active LinkedIn presence, and healthcare-industry earned media supporting demand generation. The company is privately held, has not disclosed any external funding rounds, and currently operates only within the United States.

Short descriptiontext

TeleDaaS is a U.S.-based medical practice (TeleDaaS PLLC) that delivers cloud-based, physician-approved personalized dosimetry planning for Y90 radioembolization cancer treatments, serving hospitals, health systems, CROs, and pharmaceutical manufacturers on a professional-services basis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEvanston, United States
HQ citystring
Evanston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
personalized dosimetry services, Y90 radioembolization planning, radiation oncology dosimetry, clinical trial dosimetry, radiopharmaceutical treatment planning
Industry1 code
PRIMARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code1 code
  • Diagnostic Imaging Centers621512
SIC code2 codes
  • Services-Health Services8000
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Radiation Oncology Dosimetry Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Dosimetry Treatment Planning Services
TypeProfessional Services
Description

TeleDaaS provides dosimetry services to hospitals and health systems for Y90 cancer treatment planning. The service helps hospitals improve revenue capture under existing CPT codes by ensuring complete, billable documentation. Services are delivered via cloud-based platform with physician oversight.

teledaas.com
2Clinical Trial Dosimetry Services
TypeProfessional Services
Description

Provides dosimetry services to clinical research organizations (CROs) and pharmaceutical manufacturers for clinical trials involving Y90 therapies. Supports drug development and clinical translation.

teledaas.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

TeleDaaS provides physician-approved personalized dosimetry plans for Y90 radioembolization cancer treatments to hospitals, healthcare practices, and clinical research organizations. The service is delivered through a cloud-based dosimetry-as-a-service platform (licensed from Mirada Medical) that integrates with existing hospital imaging workflows and reduces physician planning time by 1-2 hours per case. The company operates two service lines: clinical practice dosimetry (For The Clinical Practice) for hospitals treating liver cancer patients and research/clinical trial dosimetry (DoseLab) for pharmaceutical manufacturers and CROs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 2.3x increase in median post-treatment survival (10.7 months to 24.8 months)
+3 more records
Product overview1 text field

TeleDaaS operates as a Dosimetry-as-a-Service platform offering two integrated service lines: For The Clinical Practice provides personalized dosimetry planning for hospitals treating liver cancer with Y90 radioembolization, while For Research/Clinical Trials (DoseLab) supports pharmaceutical manufacturers and CROs conducting radiopharmaceutical clinical trials. Both services leverage a cloud-based technology platform licensed from Mirada Medical and are delivered by a team of licensed physicians, technologists, and PhD-level scientists.

Product and service3 records
1Dosimetry-as-a-Service (Y90 Treatment Planning)
CategoryRadiation Oncology Dosimetry Services
Description

Cloud-based personalized dosimetry service providing physician-approved treatment plans for Y90 radioembolization cancer treatments, reducing physician planning time by 1-2 hours per case. Targeted at hospitals and healthcare practices treating liver cancer patients with Y90.

2For The Clinical Practice (Clinical Dosimetry Service)
CategoryRadiation Oncology Dosimetry Services
Description

Dosimetry service tailored for hospitals and clinical practices treating cancer patients with Y90 radioembolization, offering streamlined workflows and comprehensive billing documentation to support full CPT-code reimbursement.

3DoseLab (For Research / Clinical Trials)
CategoryClinical Trial Dosimetry / Radiopharmaceutical Research Services
Description

Dosimetry service supporting clinical trials for radiopharmaceutical development, serving pharmaceutical manufacturers and CROs conducting trials involving Y90 therapies. Delivers clinical-grade precision dosimetry analysis to support drug development, validation, and trial compliance.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

Mirada Medical provides management, administrative, and technology services to TeleDaaS PLLC. The company licenses its cloud-based dosimetry technology platform to TeleDaaS. Mirada Medical maintains ISO 13485 and ISO 27001 compliance which TeleDaaS leverages through its service agreement. Mirada's advanced dosimetry technology has been used in multiple clinical trials including DOSISPHERE-1.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Licensor of TeleDaaS' core cloud dosimetry platform and a provider of advanced dosimetry software used in Y90 and other radiopharmaceutical trials. Directly comparable because it operates in the same dosimetry software space and even shares staff/administrative services with TeleDaaS.

2MIM Software
TypeEmerging player
Description

Provider of medical imaging analysis software, including solutions used in radiation therapy and radiopharmaceutical dosimetry workflows. Comparable because it offers software tools that hospitals could use in place of TeleDaaS' outsourced dosimetry service.

TypeEmerging player
Description

Developer of treatment planning systems (RayStation) used in radiation therapy and emerging radiopharmaceutical workflows. Comparable because it competes for the same hospital treatment planning budget and increasingly supports Y90-style dosimetry.

TypeBroad incumbent
Description

Developer of radiation therapy systems (CyberKnife, TomoTherapy) with associated treatment planning software. Comparable as a broader radiation oncology incumbent whose planning tools overlap with dosimetry workflows.

TypeBroad incumbent
Description

Global leader in radiation oncology treatment planning software and systems. Comparable because it provides enterprise treatment planning platforms that overlap with the dosimetry planning step TeleDaaS performs for Y90.

TypeBroad incumbent
Description

Manufacturer of SIR-Spheres Y90 resin microspheres, the main alternative to TheraSphere. Comparable because it competes in the Y90 radioembolization market that drives demand for TeleDaaS' dosimetry planning service.

TypeBroad incumbent
Description

Global provider of radiation therapy and radiosurgery hardware and software. Comparable because it sells into the same hospital radiation oncology departments that purchase TeleDaaS' dosimetry service.

TypeEmerging player
Description

Provider of software-driven treatment planning and image-guided intervention tools used in radiation oncology and interventional radiology. Comparable because it offers planning software that competes for the same hospital IT budget that funds TeleDaaS engagements.

TypeBroad incumbent
Description

Manufacturer of TheraSphere Y90 radioembolization microspheres and the sponsor of the DOSISPHERE-1 trial. Comparable because it sits in the same Y90 treatment workflow and benefits from broader adoption of personalized dosimetry that TeleDaaS provides.

10Philips Radiation Oncology
TypeBroad incumbent
Description

Offers imaging, simulation, and treatment planning solutions across radiology and oncology. Comparable because large hospital systems may consolidate dosimetry workflows onto Philips platforms instead of using a specialist like TeleDaaS.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TeleDaaS

Radiation Oncology Dosimetry Servicesteledaas.com

TeleDaaS is a U.S.-based medical practice (TeleDaaS PLLC) that delivers cloud-based, physician-approved personalized dosimetry planning for Y90 radioembolization cancer treatments, serving hospitals, health systems, CROs, and pharmaceutical manufacturers on a professional-services basis.

What TeleDaaS does

TeleDaaS is a U.S.-based medical practice (TeleDaaS PLLC, Illinois) that delivers cloud-based, physician-approved personalized dosimetry plans for Y90 radioembolization cancer treatments, primarily targeting hospitals, health systems, and physician practices treating liver cancer. The service is positioned around the clinical finding that personalized dosimetry substantially improves patient outcomes—referenced DOSISPHERE-1 trial data shows 2.3x improvement in median survival and an 8-fold increase in eligibility for curative surgery versus standard dosimetry—while also capturing full reimbursement under existing CPT codes by ensuring complete, billable documentation (the company states 99% of sites may be underbilling without proper dosimetry documentation). The product reduces physician time by 1-2 hours per case, is delivered entirely via cloud with no on-premise IT installation, and integrates with existing hospital imaging workflows.

The core technology is a dosimetry-as-a-service platform licensed from Mirada Medical Ltd., whose software carries ISO 13485 and ISO 27001 certifications and has been used across multiple clinical trials. TeleDaaS operates two service lines: "For The Clinical Practice" (treatment planning for hospitals treating Y90 patients) and "DoseLab" (research/clinical-trial dosimetry for CROs and pharmaceutical manufacturers developing radiopharmaceuticals). The team is small (1-10 employees) and is led by Co-Founder/CEO Dr. Shamar Young (Chief of Interventional Radiology at the University of Arizona), Co-Founder/COO Shelby Schweitzer, and CMO Dr. Mark Crockett, supported by PhD-level scientific advisors with over 90 years of combined experience in medical imaging, physics, and clinical translation.

TeleDaaS makes money by selling dosimetry treatment planning as a professional service to enterprise healthcare buyers on a consultative, quote-based model with a pilot program for early adopters. Its go-to-market is sales-led and direct, targeting U.S. hospitals, health systems, CROs, and pharmaceutical manufacturers, with thought-leadership content, an active LinkedIn presence, and healthcare-industry earned media supporting demand generation. The company is privately held, has not disclosed any external funding rounds, and currently operates only within the United States.

TeleDaaS firmographics

Firmographics
Name
TeleDaaS
Legal name
TeleDaaS PLLC
Website
https://teledaas.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
TeleDaaS is a U.S.-based medical practice (TeleDaaS PLLC) that delivers cloud-based, physician-approved personalized dosimetry planning for Y90 radioembolization cancer treatments, serving hospitals, health systems, CROs, and pharmaceutical manufacturers on a professional-services basis.
Ownership category
akta.pro rank

TeleDaaS industry classification

Industry
Product category
Radiation Oncology Dosimetry Services
NAICS
Diagnostic Imaging Centers (621512)
SIC
Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Personalized dosimetry services
  • Y90 radioembolization planning
  • Radiation oncology dosimetry
  • Clinical trial dosimetry
  • Radiopharmaceutical treatment planning

Where TeleDaaS is headquartered

Location

Headquarters

HQ city
Evanston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TeleDaaS business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Dosimetry Treatment Planning Services: TeleDaaS provides dosimetry services to hospitals and health systems for Y90 cancer treatment planning. The service helps hospitals improve revenue capture under existing CPT codes by ensuring complete, billable documentation. Services are delivered via cloud-based platform with physician oversight.
  2. Clinical Trial Dosimetry Services: Provides dosimetry services to clinical research organizations (CROs) and pharmaceutical manufacturers for clinical trials involving Y90 therapies. Supports drug development and clinical translation.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

TeleDaaS product offering

Product offering

Core offering

TeleDaaS provides physician-approved personalized dosimetry plans for Y90 radioembolization cancer treatments to hospitals, healthcare practices, and clinical research organizations. The service is delivered through a cloud-based dosimetry-as-a-service platform (licensed from Mirada Medical) that integrates with existing hospital imaging workflows and reduces physician planning time by 1-2 hours per case. The company operates two service lines: clinical practice dosimetry (For The Clinical Practice) for hospitals treating liver cancer patients and research/clinical trial dosimetry (DoseLab) for pharmaceutical manufacturers and CROs.

Product overview

TeleDaaS operates as a Dosimetry-as-a-Service platform offering two integrated service lines: For The Clinical Practice provides personalized dosimetry planning for hospitals treating liver cancer with Y90 radioembolization, while For Research/Clinical Trials (DoseLab) supports pharmaceutical manufacturers and CROs conducting radiopharmaceutical clinical trials. Both services leverage a cloud-based technology platform licensed from Mirada Medical and are delivered by a team of licensed physicians, technologists, and PhD-level scientists.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dosimetry-as-a-Service (Y90 Treatment Planning) Cloud-based personalized dosimetry service providing physician-approved treatment plans for Y90 radioembolization cancer treatments, reducing physician planning time by 1-2 hours per case. Targeted at hospitals and healthcare practices treating liver cancer patients with Y90.
  • For The Clinical Practice (Clinical Dosimetry Service) Dosimetry service tailored for hospitals and clinical practices treating cancer patients with Y90 radioembolization, offering streamlined workflows and comprehensive billing documentation to support full CPT-code reimbursement.
  • DoseLab (For Research / Clinical Trials) Dosimetry service supporting clinical trials for radiopharmaceutical development, serving pharmaceutical manufacturers and CROs conducting trials involving Y90 therapies. Delivers clinical-grade precision dosimetry analysis to support drug development, validation, and trial compliance.

Quantifiable outcome

  • 2.3x increase in median post-treatment survival (10.7 months to 24.8 months)
  • +3 more outcomes

Companies that use TeleDaaS

Customer profile

Segments2 records

Ideal customer profiles2 records

TeleDaaS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

TeleDaaS partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Mirada Medical Ltd.coreTechnology or IntegrationMirada Medical provides management, administrative, and technology services to TeleDaaS PLLC. The company licenses its cloud-based dosimetry technology platform to TeleDaaS. Mirada Medical maintains ISO 13485 and ISO 27001 compliance which TeleDaaS leverages through its service agreement. Mirada's advanced dosimetry technology has been used in multiple clinical trials including DOSISPHERE-1.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

TeleDaaS competitors and assessment

Company assessment

Direct peers

  • Mirada Medical: Licensor of TeleDaaS' core cloud dosimetry platform and a provider of advanced dosimetry software used in Y90 and other radiopharmaceutical trials. Directly comparable because it operates in the same dosimetry software space and even shares staff/administrative services with TeleDaaS.

Emerging players

  • MIM Software: Provider of medical imaging analysis software, including solutions used in radiation therapy and radiopharmaceutical dosimetry workflows. Comparable because it offers software tools that hospitals could use in place of TeleDaaS' outsourced dosimetry service.
  • RaySearch Laboratories: Developer of treatment planning systems (RayStation) used in radiation therapy and emerging radiopharmaceutical workflows. Comparable because it competes for the same hospital treatment planning budget and increasingly supports Y90-style dosimetry.
  • Brainlab: Provider of software-driven treatment planning and image-guided intervention tools used in radiation oncology and interventional radiology. Comparable because it offers planning software that competes for the same hospital IT budget that funds TeleDaaS engagements.

Broad incumbents

  • Accuray: Developer of radiation therapy systems (CyberKnife, TomoTherapy) with associated treatment planning software. Comparable as a broader radiation oncology incumbent whose planning tools overlap with dosimetry workflows.
  • Varian Medical Systems (Siemens Healthineers): Global leader in radiation oncology treatment planning software and systems. Comparable because it provides enterprise treatment planning platforms that overlap with the dosimetry planning step TeleDaaS performs for Y90.
  • Sirtex Medical: Manufacturer of SIR-Spheres Y90 resin microspheres, the main alternative to TheraSphere. Comparable because it competes in the Y90 radioembolization market that drives demand for TeleDaaS' dosimetry planning service.
  • Elekta: Global provider of radiation therapy and radiosurgery hardware and software. Comparable because it sells into the same hospital radiation oncology departments that purchase TeleDaaS' dosimetry service.
  • Boston Scientific (TheraSphere): Manufacturer of TheraSphere Y90 radioembolization microspheres and the sponsor of the DOSISPHERE-1 trial. Comparable because it sits in the same Y90 treatment workflow and benefits from broader adoption of personalized dosimetry that TeleDaaS provides.
  • Philips Radiation Oncology: Offers imaging, simulation, and treatment planning solutions across radiology and oncology. Comparable because large hospital systems may consolidate dosimetry workflows onto Philips platforms instead of using a specialist like TeleDaaS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

TeleDaaS social profiles

Digital presence

TeleDaaS compliance and trust

Trust signal

Compliance3 records

TeleDaaS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TeleDaaS leadership team

Management profile

Number of profiles

Profiles4 records

TeleDaaS funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TeleDaaS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TeleDaaS

What does TeleDaaS do?

TeleDaaS provides physician-approved personalized dosimetry plans for Y90 radioembolization cancer treatments to hospitals, healthcare practices, and clinical research organizations. The service is delivered through a cloud-based dosimetry-as-a-service platform (licensed from Mirada Medical) that integrates with existing hospital imaging workflows and reduces physician planning time by 1-2 hours per case. The company operates two service lines: clinical practice dosimetry (For The Clinical Practice) for hospitals treating liver cancer patients and research/clinical trial dosimetry (DoseLab) for pharmaceutical manufacturers and CROs.

Is TeleDaaS a public or private company?

TeleDaaS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was TeleDaaS founded?

TeleDaaS was founded in 2021. It employs 1 to 10 people.

Where is TeleDaaS based?

TeleDaaS is headquartered in Evanston, United States, in the North America region.

How does TeleDaaS make money?

Two revenue lines are on record. Dosimetry Treatment Planning Services are the primary driver. The others are clinical Trial Dosimetry Services.

Who are TeleDaaS's main competitors?

Mirada Medical is listed as a direct peer. Emerging players are MIM Software, RaySearch Laboratories and Brainlab. Broad incumbents are Accuray, Varian Medical Systems (Siemens Healthineers), Sirtex Medical, Elekta, Boston Scientific (TheraSphere) and Philips Radiation Oncology.

Does TeleDaaS have an API?

No public API is recorded for TeleDaaS.

What industry is TeleDaaS in?

TeleDaaS's product category is Radiation Oncology Dosimetry Services. Its primary akta.pro industry code is HLALAGAH, Oncology Telemedicine Platforms. Its NAICS code is 621512 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals